Artiva Biotherapeutics, Inc. (ARTV)

NASDAQ:
ARTV
| Latest update: May 3, 2026, 6:02 PM

Stock events for Artiva Biotherapeutics, Inc. (ARTV)

Artiva Biotherapeutics' stock has experienced significant growth and volatility. The share price increased by 211.06% over the past year. Recent events impacting the stock include the release of full-year 2025 financial results, participation in healthcare conferences, appointment of a new CFO and board member, presentation of AlloNK cost-effectiveness data, and reports of positive initial safety data from clinical trials. Analyst ratings have varied, with an average rating of "Moderate Buy" and an average price target of $18.67.

Demand Seasonality affecting Artiva Biotherapeutics, Inc.’s stock price

There is no information available regarding demand seasonality for Artiva Biotherapeutics' products and services. Demand for its products is likely driven by medical need rather than seasonal patterns.

Overview of Artiva Biotherapeutics, Inc.’s business

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for autoimmune diseases and cancers. Their primary product candidate, AlloNK, is being evaluated in clinical trials for B-cell driven autoimmune diseases, with refractory rheumatoid arthritis as the lead indication. The company's pipeline also includes CAR-NK cell candidates targeting solid and hematologic cancers, such as AB-201 for solid tumors and AB-205 for hematological malignancies.

ARTV’s Geographic footprint

Artiva Biotherapeutics, Inc. is headquartered in San Diego, California, with R&D and cGMP cell production facilities. The company also utilizes the research and manufacturing capabilities of its partner, GC Cell, in the Republic of Korea. Artiva holds exclusive worldwide rights, excluding Asia, Australia, and New Zealand, to GC Cell's NK cell manufacturing technology and programs.

ARTV Corporate Image Assessment

Artiva Biotherapeutics' brand reputation has been influenced by analyst ratings and clinical trial progress. The company has received a mix of ratings, with an average rating of "Moderate Buy". Key events influencing its reputation include the FDA Fast Track Designation for AlloNK, positive initial safety data for AlloNK in autoimmune diseases, appointment of new leadership, financial results indicating stability, and analyst downgrades introducing some negative sentiment.

Ownership

Artiva Biotherapeutics, Inc. has a significant number of institutional owners and shareholders. As of April 9, 2026, 36 institutional owners and shareholders held a total of 16,986,122 shares. Major institutional owners include RA Capital Management, L.P., 5AM Venture Management, LLC, and VR Adviser, LLC.

Price Chart

$10.80

5.47%
(1 month)

Top Shareholders

RA Capital Management LP
40.44%
5AM Venture Management LLC
9.66%
Venrock Associates
6.61%
GFH HFEVA LLC
2.75%
venbio Partners LP
2.66%
Franklin Resources, Inc.
2.14%
Revelation Partners LLC
1.23%
The Vanguard Group, Inc.
1.01%

Trade Ideas for ARTV

Today

Sentiment for ARTV

News
Social

Buzz Talk for ARTV

Today

Social Media

FAQ

What is the current stock price of Artiva Biotherapeutics, Inc.?

As of the latest update, Artiva Biotherapeutics, Inc.'s stock is trading at $10.80 per share.

What’s happening with Artiva Biotherapeutics, Inc. stock today?

Today, Artiva Biotherapeutics, Inc. stock is up by 5.47%, possibly due to news.

What is the market sentiment around Artiva Biotherapeutics, Inc. stock?

Current sentiment around Artiva Biotherapeutics, Inc. stock is positive, based on recent news, trading volume, and analyst opinions.

Is Artiva Biotherapeutics, Inc.'s stock price growing?

Over the past month, Artiva Biotherapeutics, Inc.'s stock price has increased by 5.47%.

How can I buy Artiva Biotherapeutics, Inc. stock?

You can buy Artiva Biotherapeutics, Inc. stock through any brokerage platform, such as e.g., Robinhood, Fidelity, E*TRADE, by searching for the ticker symbol ARTV

Who are the major shareholders of Artiva Biotherapeutics, Inc. stock?

Major shareholders of Artiva Biotherapeutics, Inc. include institutions such as RA Capital Management LP (40.44%), 5AM Venture Management LLC (9.66%), Venrock Associates (6.61%) ... , according to the latest filings.